Compare GCT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCT | VOR |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2021 | 2021 |
| Metric | GCT | VOR |
|---|---|---|
| Price | $50.03 | $23.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $33.00 | ★ $45.33 |
| AVG Volume (30 Days) | 728.4K | ★ 824.8K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.70 | N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $1,161,042,000.00 | N/A |
| Revenue This Year | $14.43 | N/A |
| Revenue Next Year | $6.78 | N/A |
| P/E Ratio | $23.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.17 | $1.90 |
| 52 Week High | $56.27 | $49.95 |
| Indicator | GCT | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 78.49 | 66.31 |
| Support Level | $36.09 | $11.62 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.75 | 1.30 |
| MACD | 1.19 | 0.21 |
| Stochastic Oscillator | 79.54 | 78.34 |
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia with resellers in the U.S., Asia, and Europe to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price. It earns the majority of its revenue from the United States.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.